ES2090131T3 - Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas. - Google Patents

Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas.

Info

Publication number
ES2090131T3
ES2090131T3 ES90907638T ES90907638T ES2090131T3 ES 2090131 T3 ES2090131 T3 ES 2090131T3 ES 90907638 T ES90907638 T ES 90907638T ES 90907638 T ES90907638 T ES 90907638T ES 2090131 T3 ES2090131 T3 ES 2090131T3
Authority
ES
Spain
Prior art keywords
vehicle
agent
tumor
tissue
antineoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90907638T
Other languages
English (en)
Inventor
Dennis D Pietronigro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2090131T3 publication Critical patent/ES2090131T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTAN SOLUCIONES ANTINEOPLASTICAS PARA EL SUMINISTRO INTRATUMORAL DIRECTO. LAS SOLUCIONES SE FORMULAN UTILIZANDO AGENTES ANTINEOPLASTICOS DISUELTOS EN VEHICULOS SOLVENTES, QUE SE PUEDEN MEZCLAR EN AGUA, ORGANICOS. EL VEHICULO SE SELECCIONA DE UNA MANERA TAL QUE A) EL AGENTE SE DISUELVE EN EL VEHICULO, B) EL AGENTE ES ESTABLE Y BIODISPONIBLE EN EL VEHICULO Y C) EL VEHICULO SE ESPARCE FACILMENTE Y PENETRA EN EL TEJIDO TUMOROSO. LA SOLUCION SE INYECTA DIRECTAMENTE EN EL TUMOR Y, A MEDIDA QUE EL VEHICULO PENETRA EN EL TEJIDO DEL TUMOR TRANSPORTA EL AGENTE CON EL. DE ESTA MANERA LOS NIVELES TERAPEUTICAMENTE ACEPTABLES DE AGENTE ANTINEOPLASTICO SON SUMINISTRADOS DE MANERA RAPIDA Y EFICAZ Y DISEMINADOS EN LA MASA TUMOROSA SIN QUE SE DISEMINE O SE DISEMINE MUY POCO EN EL TEJIDO SANO QUE LO RODEA.
ES90907638T 1989-05-09 1990-05-08 Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas. Expired - Lifetime ES2090131T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/349,410 US5051257A (en) 1989-05-09 1989-05-09 Antineoplastic solution and method for treating neoplasms

Publications (1)

Publication Number Publication Date
ES2090131T3 true ES2090131T3 (es) 1996-10-16

Family

ID=23372285

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90907638T Expired - Lifetime ES2090131T3 (es) 1989-05-09 1990-05-08 Solucion antineoplasica y procedimiento para el tratamiento de neoplasmas.

Country Status (9)

Country Link
US (1) US5051257A (es)
EP (1) EP0471751B1 (es)
JP (1) JP3101702B2 (es)
AT (1) ATE141162T1 (es)
AU (1) AU640657B2 (es)
CA (1) CA2055493C (es)
DE (1) DE69028102T2 (es)
ES (1) ES2090131T3 (es)
WO (1) WO1990013289A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US6229145B1 (en) * 1992-01-22 2001-05-08 Pem Technologies, Inc. Dedicated apparatus and method emission mammography
US5519221A (en) * 1992-01-22 1996-05-21 Ansel M. Schwartz Dedicated apparatus and method for emission mammography
SE9202128D0 (sv) * 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
ATE220894T1 (de) * 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US6322815B1 (en) 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
ATE232089T1 (de) * 1994-11-10 2003-02-15 Univ Kentucky Res Found Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6753005B1 (en) 1997-12-31 2004-06-22 Direct Therapeutics, Inc. Method for tissue perfusion
AU746153B2 (en) * 1997-12-31 2002-04-18 Direct Therapeutics, Inc. Method for tissue perfusion
US20050255039A1 (en) * 1998-06-26 2005-11-17 Pro Surg, Inc., A California Corporation Gel injection treatment of breast, fibroids & endometrial ablation
SE9803482D0 (sv) 1998-10-13 1998-10-13 Anders Holmberg Ion exchange tumor targeting (IETT)
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2484383C (en) * 2002-07-12 2016-05-31 Cook Incorporated Medical device coated with a bioactive agent
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
RU2250087C1 (ru) * 2004-06-16 2005-04-20 Институт Мозга Человека Российской Академии Наук (Имч Ран) Способ лечения глиальных новообразований мозга
WO2007085026A2 (en) * 2006-01-20 2007-07-26 The Board Of Regents Of The University Of Texas System Compositions and methods for the direct therapy of tumors
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010036702A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8541748B2 (en) * 2009-06-29 2013-09-24 General Electric Company System and method for performing nuclear mammography imaging
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING
CA2796620A1 (en) * 2010-06-04 2011-12-08 North-West University Injectable formulation
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
CN114929213A (zh) * 2020-04-13 2022-08-19 美国纳米食品药品公司 碱性化疗药瘤内注射剂组合物
WO2021256427A1 (ja) * 2020-06-15 2021-12-23 株式会社Kortuc 抗がん療法の増感剤
US11459567B2 (en) 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4558690A (en) * 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
EP0086627B1 (en) * 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
DE3513938A1 (de) * 1985-04-18 1986-10-23 Merck Patent Gmbh, 6100 Darmstadt Cytostatikahaltiges pharmakadepot
EP0254902B1 (de) * 1986-07-11 1991-08-28 ASTA Pharma Aktiengesellschaft Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas

Also Published As

Publication number Publication date
CA2055493A1 (en) 1990-11-10
DE69028102T2 (de) 1997-01-23
EP0471751B1 (en) 1996-08-14
EP0471751A4 (en) 1992-07-22
JP3101702B2 (ja) 2000-10-23
AU5636090A (en) 1990-11-29
ATE141162T1 (de) 1996-08-15
CA2055493C (en) 2001-04-17
AU640657B2 (en) 1993-09-02
JPH04506659A (ja) 1992-11-19
EP0471751A1 (en) 1992-02-26
DE69028102D1 (de) 1996-09-19
WO1990013289A1 (en) 1990-11-15
US5051257A (en) 1991-09-24

Similar Documents

Publication Publication Date Title
EP0471751A4 (en) Antineoplastic solution and method for treating neoplasms
BR9712599A (pt) Processos para o tratamento de um volume particular, de câncer e de um volume de tecido canceroso em tecido e para produzir pelo menos um agente molecular foto-ativo num volume particular de material e aparelhos para o tratamento de um volume particular de tecido de planta ou de animal e para a administração de um tratamento médico foto-dinâmico
SE8803087L (sv) Ett nytt saett foer behandling av erektil dysfunktion
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
DE69329112D1 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
EP0933995A4 (en) METHOD OF TREATING ENDOTHELIAL LESIONS
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
GB9409281D0 (en) Transdermal device
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
EA199900553A1 (ru) Чрескожная терапевтическая система
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
AR005962A1 (es) Aparato y composicion para la limpieza de una superficie
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
CO5050298A1 (es) Metodo y composicion para tratar impotencia
BR9912773A (pt) Processo e aparelho para o tratamento tópico de tecido doente e processo para o tratamento de doenças em vasos do sistema circulatório
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
TR28228A (tr) Deri gönlerinin islak muamelesi.
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 471751

Country of ref document: ES

FG2A Definitive protection

Ref document number: 471751

Country of ref document: ES